Skip to main content

Superficial Femoral Artery Stenosis

0
Pipeline Programs
4
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Medinol
MedinolIsrael - Tel Aviv
1 program
ChampioNIR Ridaforolimus Eluting Peripheral Stent SystemN/A1 trial
Active Trials
NCT06410313Recruiting30Est. Feb 2030
Boston Scientific
Boston ScientificCA - Valencia
1 program
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) LesionsN/A1 trial
Active Trials
NCT01327950Completed86Est. Nov 2013
Cordis
CordisFL - Miami Lakes
1 program
S.M.A.R.T.™ Nitinol Stent SystemN/A1 trial
Active Trials
NCT07338890Not Yet Recruiting240Est. May 2026
Abbott
AbbottABBOTT PARK, IL
1 program
femoropopliteal revascularization for TASC C or TASC D lesionN/A1 trial
Active Trials
NCT04434586Recruiting166Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
CordisS.M.A.R.T.™ Nitinol Stent System
MedinolChampioNIR Ridaforolimus Eluting Peripheral Stent System
Abbottfemoropopliteal revascularization for TASC C or TASC D lesion
Boston ScientificEfficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

Clinical Trials (4)

Total enrollment: 522 patients across 4 trials

NCT07338890CordisS.M.A.R.T.™ Nitinol Stent System

Post-Market Clinical Follow-Up of S.M.A.R.T. Family of Stents in Treating Iliac and Femoropopliteal Artery Disease

Start: Jan 2026Est. completion: May 2026240 patients
N/ANot Yet Recruiting
NCT06410313MedinolChampioNIR Ridaforolimus Eluting Peripheral Stent System

First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease

Start: Aug 2024Est. completion: Feb 203030 patients
N/ARecruiting
NCT04434586Abbottfemoropopliteal revascularization for TASC C or TASC D lesion

Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions

Start: Jun 2020Est. completion: Jun 2026166 patients
N/ARecruiting
NCT01327950Boston ScientificEfficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions

Start: Oct 2010Est. completion: Nov 201386 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 522 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.